A Simple and Fast Method for the Simultaneous Detection of Nine Fibroblast Growth Factor Receptor 3 Mutations in Bladder Cancer and Voided Urine
- 1 November 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (21) , 7743-7748
- https://doi.org/10.1158/1078-0432.ccr-05-1045
Abstract
Purpose: Mutations in the fibroblast growth factor receptor 3 (FGFR3) occur in 50% of primary bladder tumors. An FGFR3 mutation is associated with good prognosis, illustrated by significantly lower percentage of patients with progression and disease-specific mortality. FGFR3 mutations are especially prevalent in low grade/stage tumors, with pTa tumors harboring mutations in 85% of the cases. These tumors recur in 70% of patients. Efficient FGFR3 mutation detection for prognostic purposes and for detection of recurrences in urine is an important clinical issue. In this paper, we describe a simple assay for the simultaneous detection of nine different FGFR3 mutations. Experimental Design: The assay consists of one multiplex PCR, followed by extension of primers for each mutation with a labeled dideoxynucleotide. The extended primers are separated by capillary electrophoresis, and the identity of the incorporated nucleotide indicates the presence or absence of a mutation. Results: The assay was found to be more sensitive than single-strand conformation polymorphism analysis. Mutations could still be detected with an input of only 1 ng of genomic DNA and in a 20-fold excess of wild-type DNA. Moreover, in urine samples from patients with a mutant tumor, the sensitivity of mutation detection was 62%. Conclusions: We have developed a fast, easy to use assay for the simultaneous detection of FGFR3 mutations, which can be of assistance in clinical decision-making and as an alternative for the follow-up of patients by invasive cystoscopy for the detection of recurrences in urine.Keywords
This publication has 16 references indexed in Scilit:
- FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinomaOncogene, 2005
- A SURVEILLANCE SCHEDULE FOR G1Ta BLADDER CANCER ALLOWING EFFICIENT USE OF CHECK CYSTOSCOPY AND SAFE DISCHARGE AT 5 YEARS BASED ON A 25-YEAR PROSPECTIVE DATABASEJournal of Urology, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detectionCancer, 2003
- Molecular Grading of Urothelial Cell Carcinoma With Fibroblast Growth Factor Receptor 3 and MIB-1 is Superior to Pathologic Grade for the Prediction of Clinical OutcomeJournal of Clinical Oncology, 2003
- Bladder cancerCurrent Opinion in Oncology, 2003
- Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disordersEuropean Journal of Human Genetics, 2002
- Frequent FGFR3 Mutations in Papillary Non-Invasive Bladder (pTa) TumorsThe American Journal of Pathology, 2001
- Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinomaOncogene, 2001
- The Early Detection and Diagnosis of Bladder Cancer: A Critical Review of the OptionsEuropean Urology, 2001